Одну секунду
Что-то сучилось. Попробуйте еще раз.
DPP 4 смотреть последние обновления за сегодня на .
A simple explanation of how sitagliptin, exenatide and other DDP-4 inhibitors and GLP-1 mimetics work for the treatment of Type 2 Diabetes. Zero to Finals Medicine book: UK: 🤍 US: 🤍 Zero to Finals Paediatrics book: UK: 🤍 US: 🤍 Zero to Finals Obstetrics and Gynaecology book: UK: 🤍 US: 🤍 Website: 🤍 Notes: 🤍 Multiple Choice Questions: 🤍 Instagram: 🤍 Facebook: 🤍 Twitter: 🤍 DISCLAIMER: This video is for education and entertainment only, and is not medical advice. This video should NOT be used for medical advice or to guide clinical practice. The Zero to Finals content should not be used in any way to guide medical decision making. Zero to Finals takes no responsibility for any actions taken or not taken based on the information provided. Local and national guidelines and senior clinicians are there to help you make decisions, not YouTube videos. If you need medical advice or information, seek it from an appropriately trained and licenced doctor or healthcare provider that can address your individual needs. Zero to Finals cannot guarantee the accuracy of information in this video. Please highlight any errors you notice in the comments below - thank you.
DPP-4 is a serine protease that is widely distributed throughout the body, expressed as an ectoenzyme on endothelial cells, on the surface of T-lymphocytes, and in a circulating form. DPP-4 cleaves the two N-terminal amino acids from peptides with a proline or alanine in the second position. Although there are many potential substrates for this enzyme, it seems to be especially critical for the inactivation of GLP-1 and GIP glucose-dependent insulinotropic polypeptide; gastric inhibitory peptide . DPP-4 inhibitors increase the AUC of GLP-1 and GIP when their secretion is by a meal. Several agents provide nearly complete and long-lasting inhibition of DPP-4, thereby increasing the proportion of active GLP-1 from 10-20% of total circulating GLP-1 immunoreactivity to nearly 100%. Two of these, sitagliptin and saxagliptin are now available in the U.S.; a third, vildagliptin, is available in the E.U.; a fourth compound, alogliptin, is in advanced stages of clinical trials. Sitagliptin and alogliptin are competitive inhibitors of DPP-4, whereas vildagliptin and saxagliptin bind the enzyme covalently. Despite these differences, all four drugs can be given in doses that lower measurable activity of DPP-4 by more than 95% for 12 hours. This causes a greater than 2-fold elevation of plasma concentrations of active GIP and GLP-1 and is associated with increased insulin secretion, reduced glucagon levels, and improvements in both fasting and postprandial hyperglycemia. Inhibition of DPP-4 does not appear to have direct effects on insulin sensitivity, gastric motility, or satiety, nor does chronic treatment with DPP-4 inhibitors affect body weight. DPP-4 inhibitors, used as monotherapy in type 2 diabetic patients, reduced HbA1c levels by an average ∼0.8%. These compounds are also effective for chronic glucose control when added to the treatment of diabetic patients receiving metformin, thiazolidinediones, sulfonylureas, and insulin. The effects of DPP-4 inhibitors in combination regimens appear to be additive. The recommended dose of sitagliptin is 100 mg once daily. The recommended dose of saxagliptin is 5 mg once daily. Absorption, Distribution, Metabolism, and Excretion: DPP-4 inhibitors are absorbed effectively from the small intestine. They circulate in primarily in unbound form and are excreted mostly unchanged in the urine. DPP-4 inhibitors do not bind to albumin, nor do they affect the hepatic cytochrome oxidase system. Both sitagliptin and saxagliptin are excreted renally, and lower doses should be used in patients with reduced renal function. Sitagliptin has minimal metabolism by hepatic microsomal enzymes. Saxagliptin is metabolized by CYP 3A4/5 to an active metabolite. Adverse Effects and Drug Interactions. There are no consistent adverse effects that have been noted in clinical trials with any of the DPP-4 inhibitors. With few exceptions the incidence of adverse effects in drug-treated and placebo-treated patients has been similar. DPP-4 is expressed on lymphocytes; in the immunology literature, the enzyme is referred to as CD26. Although there is some evidence of minor effects on in vitro lymphocyte function with DPP-4 inhibitors, there is no evidence from clinical studies of major adverse effects in humans. This area bears scrutiny as more patients are treated with these compounds.
This animated video summarizes a network meta-analysis of randomized clinical trials comparing the effects of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality in patients with type 2 diabetes. Read the article at: 🤍 Key Points: Question: How do sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors compare in reducing mortality and cardiovascular events in patients with type 2 diabetes? Findings: In this network meta-analysis that includes 236 trials with 176 310 participants, the use of SGLT-2 inhibitors or GLP-1 agonists was significantly associated with lower all-cause mortality compared with the control groups (placebo or no treatment) (hazard ratio [HR], 0.80, and HR, 0.88, respectively) and with DPP-4 inhibitors (HR, 0.78, and HR, 0.86, respectively). Meaning: In patients with type 2 diabetes, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with better mortality outcomes than DPP-4 inhibitors.
Nach dem Essen sorgen Hormone aus dem Darm dafür, dass die Bauchspeicheldrüse Insulin ausschüttet. Durch das Insulin nehmen die Körperzellen Zucker aus dem Blut auf. Der natürliche Gegenspieler dieser Darmhormone ist das Eiweiß DPP-4. Diabetes-Medikamente aus der Wirkstoffgruppe der DPP-4-Hemmer können dabei helfen, den Blutzuckerspiegel zu senken. Doch wie geht das? Mehr Informationen zu Diabetes-Medikamenten und der Behandlung von Diabetes finden Sie auf unserem Gesundheitsportal: 🤍 Dort finden Sie auch alle Angaben zu den Quellen, auf denen dieser Film beruht.
Study this DPP-4 Inhibitors mnemonic and other mnemonics with Pixorize. DPP-4 inhibitors are a class of drugs recognizable by their -gliptin ending, including sitagliptin, linagliptin, and saxagliptin. These drugs are used to treat type 2 diabetes mellitus by lowering blood sugar levels. Inhibition of the DPP-4 enzyme has several downstream effects, including increasing GLP-1 levels, decreasing gastric emptying and increasing satiety. These drugs also stimulate glucose-dependent insulin release, and decrease glucagon release. Side effects of these drugs include an increased risk of developing urinary infections and upper respiratory infections. Notably, these drugs typically do not cause hypoglycemia, and usually have no effect on weight in patients. Subscribe for more: 🤍 Study interactive image: 🤍 #USMLE #Step1 #Pharm #DPP4
DPP-4 Inhibitors. How to treat type 2 DM. Treatment options for type 2 DM. How DPP-4 Inhibitors work.
Diabetes Medications - DPP-4 inhibitors - Tradenames
Explore our entire animation video library at: 🤍 All videos from endocrine pharmacology: 🤍 Video Summary: GLP-1 receptor agonists are basically GLP-1 analogs resistant to degradation by DPP-4. They directly stimulate the GLP-1 receptor and cause insulin release. DPP-4 inhibitors, on the other hand, prevent the degradation of endogenous GLP-1. So the effect of GLP-1 on β cells is increased and again, more insulin is released ● More videos on Insulin and Diabetes • Mechanism of Insulin Secretion: 🤍 • Mechanism of Action of Sulfonylureas and Meglitinide Analogues: 🤍 • Oral Antidiabetic Drugs Classification: 🤍 ● Follow me at: • Facebook: 🤍 • Instagram: 🤍 DISCLAIMER: This video is for education purpose only. Although every effort is made to ensure accuracy of material, viewer should refer to the appropriate regulatory body/authorised websites, guidelines and other suitable sources of information as deemed relevant and applicable. In view of possibility of human error or changes in medical science, any person or organization involved in preparation of this work accepts no responsibility for any errors or omissions or results obtained from use of information in this video.
Diabetes Medications - DPP-4 inhibitors
Learn about DPP-4 side effects. MDs answer your diabetes questions.
Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006.[1] Glucagon increases blood glucose levels, and DPP-4 inhibitors reduce glucagon and blood glucose levels. The mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP),[2][3][4] which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels. A 2018 meta-analysis found no favorable effect of DPP-4 inhibitors on all-cause mortality, cardiovascular mortality, myocardial infarction or stroke in patients with type 2 diabetes.[5] ExamplesEdit Drugs belonging to this class are: Sitagliptin[6] (FDA approved 2006, marketed by Merck & Co. as Januvia) Vildagliptin[7] (EU approved 2007, marketed in the EU by Novartis as Galvus) Saxagliptin (FDA approved in 2009, marketed as Onglyza) Linagliptin (FDA approved in 2011, marketed as Tradjenta by Eli Lilly and Company and Boehringer Ingelheim)[8] Gemigliptin (approved in Korea in 2012, marketed by LG Life Sciences)[9] Marketed as Zemiglo Anagliptin (approved in Japan in 2012, marketed by Sanwa Kagaku Kenkyusho Co., Ltd. and Kowa Company, Ltd.)[10] Teneligliptin (approved in Japan in 2012[11]) Alogliptin (FDA approved 2013, marketed by Takeda Pharmaceutical Company) Trelagliptin (approved for use in Japan in 2015) Omarigliptin (MK-3102) (approved in Japan in 2015,[12] developed by Merck & Co.; research showed that omarigliptin can be used as once-weekly treatment and generally well-tolerated throughout the base and extension studies[13]) Evogliptin (approved for use in South Korea[14]) Gosogliptin (approved for use in Russia[15]) Dutogliptin (being developed by Phenomix Corporation), Phase III[16] Other chemicals which may inhibit DPP-4 include: Berberine, an alkaloid found in plants of the genus Berberis, inhibits dipeptidyl peptidase-4 which may at least partly explains its antihyperglycemic activity.[17] Adverse effectsEdit In those taking sulphonylureas, there is an increased risk of low blood sugar.[18] Adverse effects, including nasopharyngitis, headache, nausea, heart failure, hypersensitivity and skin reactions. The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines like sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors.[19] However, studies assessing risk of rheumatoid arthritis among DPP-4 inhibitor users have been inconclusive.[20] A 2014 review found increased risk of heart failure with saxagliptin and alogliptin, prompting the FDA in 2016 to add warnings to the relevant drug labels.[21] A 2018 meta analysis showed that use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment.[22] A 2018 observational study suggested an elevated risk of developing inflammatory bowel disease (specifically, ulcerative colitis), reaching a peak after three to four years of use and decreasing after more than four years of use.[23] CancerEdit In response to a report of precancerous changes in the pancreases of rats and organ donors treated with the DPP-4 inhibitor sitagliptin,[24][25] the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-4 inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicine, the agencies stated that they had not yet reached a final conclusion regarding a possible causative relationship.[26] A 2014 meta-analysis found no evidence for increased pancreatic cancer risk in people treated with DPP-4 inhibitors, but owing to the modest amount of data available, was not able to completely exclude possible risk.[27] Combination drugsEdit Some of the DPP-4 inhibitor drugs have gotten approval from the FDA to be used with metformin concomitantly with additive effect to increase the level of glucagon-like peptide 1 (GLP-1) which also decreases hepatic glucose production.[28]
Ozempic is a brand name for the medication semaglutide, which belongs to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). GLP-1 RAs are used to treat type 2 diabetes by helping to regulate blood sugar levels and promoting weight loss. They work by mimicking the effects of the natural hormone GLP-1, which helps to stimulate insulin production, decrease glucagon secretion, slow down stomach emptying, and reduce appetite. Semaglutide, marketed under the name Ozempic, is administered as an injectable medication. It comes in a pre-filled pen that patients can use to self-administer the medication once a week. Ozempic has been approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of type 2 diabetes. The main benefits of Ozempic include: 1. Blood Sugar Control: Ozempic helps lower blood sugar levels by stimulating the release of insulin and reducing the release of glucagon, which is a hormone that raises blood sugar levels. 2. Weight Loss: One of the notable effects of Ozempic is weight loss. Many patients experience moderate weight loss when using this medication, which can be beneficial for those with type 2 diabetes, as obesity is a common risk factor for the condition. 3. Cardiovascular Benefits: Some studies have shown that GLP-1 RAs like Ozempic might have cardiovascular benefits, including reducing the risk of major cardiovascular events in people with type 2 diabetes and established cardiovascular disease. 4. Convenience: The once-weekly dosing of Ozempic can offer a level of convenience for patients, compared to some other diabetes medications that need to be taken daily. It's important to note that Ozempic, like any medication, may have potential side effects. Common side effects can include nausea, vomiting, diarrhea, and headache. These effects are usually mild and tend to improve over time as the body adjusts to the medication. As always, it's crucial to consult with a healthcare professional before starting any new medication, including Ozempic. They can provide personalized guidance based on your medical history, current health status, and specific needs.
Mechanism of Action of DPP-4 explained by Dr. Shantanu. R. Joshi. For more info log on to 🤍oxfordmedicalacademy.com
Drug Treatment Modalities- DPP4 Inhibitors
By Julie Chaimowitz, Fiona Lu, Lori Mohs, and Amy Ni East Brunswick High School, East Brunswick, NJ Team Advisor: Mrs. Louise Jasko Winner of the Judge’s Award Second Place in the 2017 RCSB PDB Video Challenge for High School Students “Molecular View of Diabetes Treatment and Management”.
국내에서 가장 많은 사랑을 받고 있는 당뇨병 치료제, DPP4-i 이 약제가 효과가 좋고 안전한 이유는 무엇일까요? DPP-4에 대한 전반적인 이해와 약제의 특장점 및 주의사항에 대해 정수진 과장님이 알려드립니다. 출연: 정수진 과장님 00:00 시작 00:47 DPP-4 억제제란? 01:11 장호르몬 인크레틴이란? 02:07 복용 가능한 당뇨병 환자는? 03:53 장점과 주의사항은? #정수진 #당뇨약제 #당뇨병 관련기사: [인터뷰] 내분비내과 정수진 과장②, “당뇨병 치료제 중 한국인에게 최적화된 약이 있다?” 🤍 ※ 건강의료전문포털 '하이닥' 🤍 ※ 하이닥 제작편집국 촬영: 감호준PD, 신정우PD, 이관준PD 편집: 임현정PD 제작문의: hidoc🤍mcircle.biz ★빠른 전문가 답변을 원하시면, 하이닥 QnA로 문의하세요~ 🤍 ▷ 네이버 포스트 🤍 ▷ 카카오채널 🤍 ▷ 페이스북 🤍 ▷ 인스타그램 🤍 ▷ 트위터 🤍 *저작권©언론사 하이닥, 무단 전재 및 재배포 금지
In this video, we simplify the mode of action of Gliptins. #Mode of action of DPP4 inhibitors #Teneligliptin
식후혈당을 잡는데 유용하고, 저혈당이 잘 오지 않는다는 장점이 있습니다. 그런데, 같은 DPP4저해제라고 하더라도 개별 약제에 따라 조금씩 차이가 있어 그 특성을 잘 알고 사용해야겠습니다.
Doç.Dr.Fevzi Balkan Endokrinoloji ve Metabolizma Hastalıkları Uzmanı 🤍endokrin.com.tr 🤍 🤍 🤍 🤍 Balkan Endokrinoloji ve Metabolizma Hastalıkları Uzmanı 🤍endokrin.com.tr 🤍 🤍 🤍 🤍
yakulab infoでは、医薬品、薬物治療に関する情報を配信しています 【動画の概要】 糖尿病治療薬のDPP-4阻害薬を適正に使用するために、DPP-４阻害薬の特徴をまとめてみました 糖尿病治療薬が気になる DPP-4阻害薬の使い分けを知りたい という方 必見！ 【ツイッター】 🤍 お問い合わせはTwitterからお願いします 【オンライン予備校 YAKUZERO プレミアムコース】 🤍 【関連サイト】 🤍 【動画作成をリクエストしたい方】↓↓↓ 🤍 ＃薬剤師 ＃薬物治療 ＃糖尿病 ＃血糖値
Intervista al Professor Stefano Del Prato, Ordinario di Endocrinologia, Università degli studi di Pisa, Past president Società Italiana di Diabetologia
Photography trainer, John McQuiston, takes you through the new DPP 4's tool palette and histogram to show you how you can edit and create impactful images. Check out more DPP tutorials on the Canon Digital Learning Center: 🤍
#doctorenusa #usmlelatino #examenmir #eunacom Los inhibidores de la dipeptidil peptidasa-4 o DPP-4 son fármacos análogos peptídicos que actúan sobre la enzima DPP-4, anulando la acción ihhibitoria que ésta tiene sobre las hormonas llamadas incretinas. Por tanto, cuando la DPP-4 es inhibida, la vida media de las hormonas incretinas es mayor, pudiendo realizar sus acciones durante más tiempo, por lo que resultan de interés en el tratamiento antidiabético oral La concentración de GLP-1 está disminuida en la Diabetes Mellitus Tipo 2, pero su acción está intacta, de manera que al dar GLP-1 en una infusión se obtienen los efectos descritos más arriba, igual que en el individuo sano. Lo que ocurre en la DM2 es un déficit en la cuantía de GLP-1, no en su función. Los efectos de GLP-1 sobre la insulina y el glucagón se ha visto que dependen de la glucosa en la DM2, de manera que con hiperglucemia (tras las comidas con Hidratos de carbono) el GLP-1 estimula la producción de insulina y suprime la de glucagón, y cuando los niveles de glucosa están normales, la secreción de insulina disminuye y la de glucagón deja de estar suprimida. Al contrario, las sulfonilureas actúan independientemente de los niveles de glucosa en sangre, teniendo así un riesgo de producir hipoglucemias, que es algo que no ocurriría en el tratamiento en monoterapia con las incretinas (o con anuladores de su enzima inhibidora, como la sitagliptina), por lo que su efecto es más fisiológico. Las incretinas tienen una vida media muy corta y se degradan rápidamente por la enzima Di-Peptidil-Peptidasa-4 (DPP-4) y gracias a los inhibidores de esta enzima, existe la posibilidad de mantener más tiempo a estas hormonas actuando. Existen distintos ensayos clínicos con sitagliptina tanto en monoterapia como en combinación con otras opciones terapéuticas como metformina y glitazonas. Los efectos secundarios de sitagliptina que se han objetivado en todos los ensayos clínicos, tanto en monoterapia como en asociación con otras opciones terapéuticas han sido algunas alteraciones de laboratorio como el aumento de los niveles sanguíneos de ácido úrico y una disminución muy ligera de los niveles séricos de fosfatasa alcalina.
Dr. Carlos Pinto : en este video te enteraras de todos los detalles de esta familia en cuestion de su farmacologia...
당뇨약이 코로나 중증 진행을 감소시킨다? DPP-4 억제제의 모든 것! 10여 년 전 국내 도입 후 폭발적인 반응을 일으킨 DPP-4 억제제 혈당 조절은 기본 심혈관 질환 예방까지! 뚜렷한 부작용 없이 당뇨인들에게 사랑받고 있는데... 이 약이 코로나 바이러스에 관여한다? 중증 질환 진행은 물론 사망 위험까지 무려 60% 이상 감소시켰다는 놀라운 연구 결과!! 좋은 건 다 갖춘 당뇨 치료 약제 DPP-4 억제제의 모든 것 15년 당뇨 전문의 최영주 원장이 이해하기 쉽게 설명해 드립니다. 최영주 당당내과의원 당뇨병 전문의가 직접 검사,관리해드리는 전문병원입니다. 홈페이지 🤍 전화 02-392-1117 -영상이 유익하셨다면 구독, 좋아요, 알림 설정 눌러주시면 큰 힘이 됩니다 -'최영주의 당당스쿨'에서 다뤘으면 하는 주제가 있으면 제안해 주세요. 방송을 통해 궁금한 점을 풀어드리겠습니다. #코로나 #당뇨 #바이러스 #DPP-4억제제#중증질환 #사망 #부작용 #인크레틴 #GLP #식후혈당 #글루카곤 #저혈당 #설폰요소제 #심혈관질환 #염증
Les problèmes cardiaques sont fréquemment associés au diabète. Cette maladie chronique de plus en plus répandue en France et dans le monde impacte considérablement la vie des personnes qui en souffrent. Dans cette série de vidéos d’une minute maximum vous trouverez toutes les réponses aux questions que vous vous posez. Ces vidéos ont été réalisées avec des spécialistes du diabète et du cœur dans un langage accessible à tous. Les vidéos ont été réalisées en partenariat avec les laboratoires Novo Nordisk. FR22CD00001 (septembre 2022) Réf : santé publique France 2021.
Learn about DPP 4's new interface, the expanded controls, the improved processing algorithims and how to arrange your workspace to your preference. Check out more DPP tutorials on the Canon Digital Learning Center: 🤍
The mechanism of DPP4 Inhibitor Action as an Anti Diabetes Medication.
A brief description of the mechanism of action of DPP4 inhibitors, or 'gliptins', for the treatment of type II diabetes. These drugs work by inhibiting the enzyme DPP4, which prevents it from degrading GLP-1, an incretin hormone which enhances glucose-dependent insulin secretion. Drugs in this class include saxagliptin, sitagliptin and alogliptin. A more detailed overview of type II diabetes - 🤍 More treatments for type II diabetes - Metformin - 🤍 SGLT2 inhibitors - 🤍 Alpha-glucosidase inhibitors - 🤍 GLP-1 Analogues - 🤍 Sulphonylureas - 🤍 Thiazolidinediones - 🤍 Subscribe to DrugsPlus: 🤍 Related videos: How the pancreas works - 🤍 Gestational Diabetes - 🤍 Knock your GCSE, A level or university exam results out of the park with DrugsPlus. With videos on physiology, disease and drugs, this is your number one stop for anything involving medical health. Topics covered range from the heart, to the brain; from the reproductive system, to the endocrine system; from cyanide, to COVID-19. People who enjoy DrugsPlus include everyone from prospective medical students, to anyone with a general interest in drugs and disease. DrugsPlus solely exists for educational purposes and should not be used for personal medical advice, nor as an aid to self-diagnosis – always consult with your physician or healthcare professional.
La sicurezza cardiovascolare dei farmaci antidiabetici è un argomento di grande attualità. Il Prof. Francesco Giorgino ci parla, in particolare, della sicurezza cardiovascolare dei farmaci inibitori dell'enzima DPP-4 Intervista al Professor Francesco Giorgino, Ordinario di Endocrinologia e Malattie Metaboliche presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Bari Iscriviti al canale YouTube 🤍 Oppure iscritivi alla Newsletter 🤍 PharmaStar è una testata giornalistica on-line interamente dedicata al mondo del farmaco e registrata al Tribunale di Milano. Visita il sito web 🤍 Seguici su Twitter 🤍 Seguici su Facebook 🤍
Actualmente en Internado Médico Ingenieras en Biotecnología a los 16 años Step 1 USMLE, a los 20. Rotación en Surgical Intensive Care Unit, Univ. de Miami. Presidenta y Vicepresidenta del Mission:Brain UAM chapter Cada una con más de 50 cirugías mayores de neurocirugía y ortopedia, como 1er. o 2do. ayudantes. Dos trabajos en Congreso Latinoamericano de Neurocirugía Miembros de la American Association of Neurological Surgeons Las Polímatas más prolíficas en producciones de videos matemáticos, científicos y de medicina a nivel mundial. Mission:Brain, organización no lucrativa, el Dr. Quiñones-Hinojosa (Director de Neurocirugía de la Clínica Mayo, campus Florida) y el Dr. Michael Lawton (Barrow Neurological Institute), como Presidente y Vice Presidente, para gastos neuroquirúrgicos en México y en el mundo. Construyamos puentes juntos: Donar a Mission:BRAIN: 🤍 Mission:brain: 🤍
A FREE Complete CANON Digital Photo Professional 4 Tutorial Link to download a useful DDP4 Instruction Manual: 🤍 Chapters 0:00 - Introduction 1:13 - Interface Layout 10:21 - Using Filters 12:10 - Quick Checks Function 13:46 - Bookmarks 14:45 - Collections 16:21 - Editing an Image Interface 19:44 - Perform Basic Image Adjustment Tab 29:04 - Adjusting Sharpness 31:29 - Adjust Image Detail Tab (Removing Noise) 34:25 - Adjust Image Tone Curves Tab 37:37 - Adjust Image Colours 43:01 - Perform Image Lens correction 49:05 - Crop and Rotate Images 52:29 - Adjust Specific Areas Tab 58:28 - Remove dust from Images or apply a stamp 1:04:22 - Saving your Images 1:06:14 - Applying and Saving Recipes 1:07:33 - Outro Other Canon Digital Photography Professional 4 Videos: DPP4 Beginners Tutorial 🤍 DPP4 Intermediate Tutorial 🤍 DPP4 How to use recipes 🤍 DDP4 How to adjust specific areas 🤍 DDP4 Add a Watermark workaround 🤍 DDP4 Remove Objects & People 🤍 DDP4 Sharpness Explained 🤍 Editing a photo from beginning to end 🤍 DPP4 Correcting Exposure 🤍 DPP4 Remote Shooting using EOS Utility 🤍 DPP4 HDR Compositing - Exposure Bracketing 🤍 DPP4 Practical Example and Moving the Moon 🤍 DPP4 Perform Image Lens Correction Tutorial 🤍 DPP4 Focus Bracketing and Depth Compositing Tutorial 🤍 DPP4 Transform a bad photo to great Black & White photo 🤍 DPP4 | Remove spots and marks from a portrait | Canon Digital Photography Professional 4 | Tutorial 🤍 As an Amazon Associate I earn from qualifying purchases. My YouTube Gear: Canon 90D 🤍 Canon BR-E1 Wireless Remote Control 🤍 RALENO LED Video Light 🤍 BACK COLOUR LIGHTS - G1s RGB Video Light 🤍 Rode Wireless Go 2 🤍 Blue Yeti Nano Black 🤍 Led Video Light, ULANZI VL49 🤍 Joby Gorillapod 3K Pro Kit 🤍
Washed out areas, loss of detail and incorrect colors are some issues photographers face in their raw images. Learn how you can easily correct these common issues in DPP 4. Check out more DPP tutorials on the Canon Digital Learning Center: 🤍
La aparición de los Inhibidores de DPP4 en el manejo de la Diabetes tipo 2 significó un parteaguas en el tratamiento de los pacientes con Diabetes. Su llegada en el 2006 abrió una nueva época hacia terapias con menos tasa de hipoglucemia , sin aumento de peso y seguras cardiovascularmente. Fáciles de usar, en su mayoría una vez al día, sin importar el horario o la relación con los alimentos sorprendió por sus pocos efectos secundarios y su gran combinabilidad con otras terapias, así como por su utilidad en etapas tempranas de la enfermedad ya sea como monoterapia o terapia combinada temprana así como en etapas avanzadas ya sea en pacientes con falla renal o que usen insulina basal. Esperemos que les sea útil como una revisión rápida para su práctica diaria Gracias por seguir a EndoTips.
◆その他の動画はこちら 「糖尿病3分間ラーニング」 🤍 ◆動画の更新情報はメールマガジンでお知らせします。 「糖尿病ネットワーク メールマガジン（無料）」 🤍 ◆3. 糖尿病の治療法 3-13. DPP-4阻害薬 🤍 ◆糖尿病ネットワーク 🤍 ※広告が出ないバージョンのDVDを発売中！ 🤍 ◆関連情報 糖尿病セミナー：薬物療法（経口薬） 🤍 糖尿病Q＆A1000：薬を使って糖尿病を治す 🤍 連載：糖尿病治療薬の特徴と服薬指導のポイント 🤍 糖尿病リソースガイド 治療薬一覧表 🤍 ネットワークアンケート：糖尿病薬の知識 🤍 ネットワークアンケート：処方された薬の服用 🤍
See how you can use the Bookmarks, folders, "Collections," filter settings and more to help organize your workspace and photos. Check out more DPP tutorials on the Canon Digital Learning Center: 🤍
O tratamento do diabetes sofreu mudanças paradigmáticas nos últimos 5 anos. Neste sentido, o curso Diabetes: Tratamento e Prática é uma oportunidade de atualização sobre as novas drogas, a sequência de introdução dessas drogas, a prevenção de complicações e o tratamento das complicações já instaladas. Proporciona conhecimento atual e prático para médicos que tratam de pacientes com diabetes, incluindo: clínicos, geriatras, cardiologistas, nefrologistas, internistas e endocrinologistas. A coordenação é do Dr. Mario Saad (FCM-Unicamp). As aulas são ministradas por especialistas com reconhecimento no meio, todos professores da Unicamp. Carga horária: 10 horas. Saiba: 🤍
Neste vídeo iremos conhecer os fármacos que atuam inibindo a enzima dipeptidil peptidase IV, a DPP-IV.
.svg){kind=small}
![[당뇨 치료약]폭발적인 반응! 당뇨약이 코로나 중증 진행을 억제한다? | 최영주의 당당스쿨 #23 혈당조절 심혈관질환 예방 적은 부작용 DPP4억제제](https://i.ytimg.com/vi/ZDVkqk1n8yM/mqdefault.jpg "[당뇨 치료약]폭발적인 반응! 당뇨약이 코로나 중증 진행을 억제한다? | 최영주의 당당스쿨 #23 혈당조절 심혈관질환 예방 적은 부작용 DPP4억제제")
